NeuroSense Therapeutics Says On Dec. 13, 2022 FDA Provided Comment That Data Submitted Do Not Support Entire Paradigm Study Duration, Says Co. Responded To Comment Providing Additional Supportive Data, Justification For Study Duration

-SEC Filing

-SEC Filing

Total
0
Shares
Related Posts
Read More

US Stocks Edge Higher; Amazon And iRobot Agree To Terminate Acquisition Deal

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 25 points on Monday. Following the market opening Monday, The Dow traded up 0.07% to 38,134.80 while the NASDAQ rose 0.04% to 15,461.42. The S&P 500 also fell, dropping, 0.04% to 4,893.17.

AMZN